June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Treatment of cystoid macular edema secondary to infectious uveitis with anti-vascular endothelial growth factor agents
Author Affiliations & Notes
  • Tyler Ogden
    University of Louisville School of Medicine, Louisville, Kentucky, United States
    San Antonio Uniformed Services Health Education Consortium, Fort Sam Houston, Texas, United States
  • Harpal Sandhu
    Ophthalmology/Visual Sciences, University of Louisville School of Medicine, Louisville, Kentucky, United States
  • Footnotes
    Commercial Relationships   Tyler Ogden, None; Harpal Sandhu, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 2175. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Tyler Ogden, Harpal Sandhu; Treatment of cystoid macular edema secondary to infectious uveitis with anti-vascular endothelial growth factor agents. Invest. Ophthalmol. Vis. Sci. 2021;62(8):2175.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Intravitreal anti-vascular endothelial growth factor (VEGF) agents have not been well studied in treatment of cystoid macular edema (CME) secondary to infectious uveitis (IU) and may prove to be an effective alternative to steroids without the risk of reactivation of latent infection. The purpose of this retrospective case series was to evaluate anti-VEGF agents as a treatment of CME secondary to IU.

Methods : This retrospective case series included patients treated for CME secondary to inactive IU. Mean change was calculated for central macular thickness (CMT), intraocular pressure (IOP), and best corrected visual acuity (BCVA) between initiation of treatment and final follow up appointments. BCVA was converted into logMAR values for analysis. A paired t test was used to evaluate for statistically significant difference.

Results : 5 eyes of 3 patients were included with underlying diagnoses of syphilitic uveitis in 2 patients (4 eyes) and herpes simplex uveitis in 1 patient (1 eye). The mean treatment course was 11 months with an average of 6 treatments per eye. Mean change in CMT after treatment was -120 µm (p=0.28). There was no statistically significant difference in BCVA before and after treatment (p=0.40). Mean IOP was 17.4 prior to treatment and 17.2 after treatment (p=0.86). Recurrence of uveitis was not observed in any eye during treatment.

Conclusions : Anti-VEGF agents are safe in eyes with inactive IU. Although statistically insignificant in this small series, there was a trend towards improved anatomical outcomes with this treatment.

This is a 2021 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×